Worldwide Cell Therapy Consumables Industry to 2031 – Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others – PRNewswire

DUBLIN, Oct. 12, 2021 /PRNewswire/ -- The "Cell Therapy Consumables Market by Type of Consumable, Type of Cell Therapy, Scale of Operation, Type of End-User and Key Geographical Regions: Industry Trends and Global Forecasts, 2021 - 2031" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market.

According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains.

Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents.

Presently, over 60 service providers are actively engaged in providing consumable/raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and/or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.

Amongst other elements, the report features:

Key Questions Answered

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE4.1. Chapter Overview4.2. Cell Therapy Kit Providers: List of Players4.3. Cell Therapy Media Providers: List of Players4.4. Cell Therapy Reagent Providers: List of Players4.5. Analysis by Type of Consumable, Type of Cell Therapy and Application Area (Grid Representation)

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Key Assumptions and Parameters5.3. Methodology5.4. Company Competitiveness: Kit Providers5.5. Company Competitiveness: Media Providers5.6. Company Competitiveness: Reagent Providers

6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS6.1. Chapter Overview6.2. Scope and Methodology6.3. Bio-Techne6.4. Miltenyi Biotec6.5. Sartorius6.6. STEMCELL Technologies6.7. Thermo Fisher Scientific

7. COMPANY PROFILES7.1. Chapter Overview7.2. Miltenyi Biotec7.2.1. Company Overview7.2.2. Product Portfolio7.2.3. Recent Developments and Future Outlook7.3. STEMCELL Technologies7.3.1. Company Overview7.3.2. Product Portfolio7.3.3. Recent Developments and Future Outlook7.4. Bio-Techne7.4.1. Company Overview7.4.2. Product Portfolio7.4.3. Recent Developments and Future Outlook7.5. Irvine Scientific7.5.1. Company Overview7.5.2. Product Portfolio7.5.3. Recent Developments and Future Outlook7.6. Thermo Fisher Scientific7.6.1. Company Overview7.6.2. Product Portfolio7.6.3. Recent Developments and Future Outlook7.7. Sartorius7.7.1. Company Overview7.7.2. Product Portfolio7.7.3. Recent Developments and Future Outlook7.8. BD Biosciences7.8.1. Company Overview7.8.2. Product Portfolio7.8.3. Recent Developments and Future Outlook7.9. Lonza7.9.1. Company Overview7.9.2. Product Portfolio7.9.3. Recent Developments and Future Outlook7.10. CellGenix7.10.1. Company Overview7.10.2. Product Portfolio7.10.3. Recent Developments and Future Outlook7.11. Corning7.11.1. Company Overview7.11.2. Product Portfolio7.11.3. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS AND INITIATIVES8.1. Chapter Overview8.2. Partnership Models8.3. Cell Therapy Consumables: Recent Partnerships and Collaborations8.4. Cell Therapy Consumables: Recent Expansions

9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS 9.1. Chapter Overview9.2. Scoring Criteria and Key Assumptions9.3. Scope and Methodology9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers9.3.1. Likely Partner Opportunities for Dendritic Cell Therapy Consumable Providers9.3.2. Likely Partner Opportunities for NK Cell Therapy Consumable Providers9.3.3. Likely Partner Opportunities for Stem Cell Therapy Consumable Providers9.3.4. Likely Partner Opportunities for T-Cell Therapy Consumable Providers

10. DEMAND ANALYSIS10.1. Chapter Overview10.2. Scope and Methodology10.3. Global Demand for Cell Therapy Consumables10.4. Global Demand for Cell Therapy Consumables for Planar Processes10.5. Global Demand for Cell Therapy Consumables for Suspension Processes10.6. Analysis by Scale of Operation10.7. Analysis by Region

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS11.1. Chapter Overview11.2. Forecast Methodology11.3. Global Outsourced Cell Therapy Consumables Market, 2021-203111.4. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Consumable11.5. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Cell Therapy11.6. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Scale of Operation11.7. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of End-User11.8. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Geography

12. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES12.1. Chapter Overview12.2. Emerging Trends Related to Cell Culture Media12.3. Automation of Cell Therapy Manufacturing Processes12.4. Single Use Systems and Technologies in Cell Therapy Manufacturing

13. IMPACT OF COVID-19 ON CELL THERAPY CONSUMABLES MARKET13.1. Chapter Overview13.2. Impact of COVID-19 Pandemic on Cell Therapy Consumables Market13.3. Impact on Future Market Opportunities for Cell Therapy Consumable Providers13.4. Current Opinions and Key Initiatives of Key Players13.5. Recuperative Strategies for Developer Businesses13.5.1. Strategies for Implementation in the Short / Mid Term13.5.2. Strategies for Implementation in the Long Term

14. CONCLUDING REMARKS14.1. Chapter Overview

15. INTERVIEW TRANSCRIPTS15.1. Chapter Overview15.2. Anant Kamath, Chief Operating Officer, Cellular Engineering Technologies15.2.1. Cellular Engineering Technologies: Key Highlights15.2.2. Interview Transcript15.3. Vishal G. Warke, Director R&D, Cell Culture and Immunology, HiMedia Laboratories and Gauri W. Page, Assistant R&D Manager, Animal Cell Culture, Himedia Laboratories15.3.1. HiMedia Laboratories: Key Highlights15.3.2. Interview Transcript

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/2t5jj1

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Follow this link:
Worldwide Cell Therapy Consumables Industry to 2031 - Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others - PRNewswire